The health fair will also offer a lung cancer screening bus and presentations covering ovarian cancer, women’s health, ...

Germline pathogenic variants contribute to 15%-20% of ovarian cancer cases, with BRCA1/2 mutations accounting for 65%-85% of these cases. Disparities in genetic testing uptake exist across racial, ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN), Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today revealed new nationwide survey results ...

Ovarian cancer (OC) remains the deadliest gynecologic malignancy, with platinum-based chemotherapies such as carboplatin serving as the standard first-line treatment. However, the emergence of ...

From different corners of the cancer journey, Lori Gilman and Dr. Mitchel Hoffman exemplify how modern medicine, genetic science, and human determination are transforming the fight against ovarian ...

Of the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could ...

A global team of doctors and researchers are using AI to better improve the treatment and survival rates of women with ...

Here’s what the experts say.